<DOC>
	<DOCNO>NCT01619046</DOCNO>
	<brief_summary>The purpose study assess safety , efficacy pharmacokinetics GreenGene™ F subject severe hemophilia A previously treat ( &gt; 150 exposure day ) Factor VIII concentrate without presence history inhibitor FVIII ( Factor VIII ) .</brief_summary>
	<brief_title>Safety , Efficacy Pharmacokinetics GreenGene™ F Previously Treated Patients With Severe Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>1 . Male female subject age ≥ 12 year time inform consent 2 . Body weight ≥ 35 kg 3 . Diagnosed severe hemophilia A . All subject must severe hemophilia A baseline FVIII &lt; 1 % activity ; &lt; 0.01 IU/mL 4 . Have ≥ 150 previous exposure day FVIII concentrate , document subject 's medical record 5 . Subjects include ondemand treatment cohort must verifiable record least three bleed episode per month average last 6 month prior enrollment 6 . Negative assay FVIII inhibitor inclusion ( &lt; 0.6BU Nijmegen assay ) 7 . Negative assay FVIII inhibitor subject file ( &lt; 0.6BU Nijmegen assay ) No history positive inhibitor allow 8 . Normal liver kidney function . 9 . Platelet count ≥ 100,000 μL 10 . Normal prothrombin time International Normalized Ratio ( INR ) &lt; 1.5 11 . Subjects receive therapy human immunodeficiency virus ( HIV ) hepatitis must stable treatment regimen 12 . Subjects must able withhold FVIII infusion approximately 72 h prior FVIII activity inhibitor assay ( 96 h participate PK sub study ) 13 . Absolute CD4 lymphocyte cell count ≥ 200 μL 14 . Signed write informed consent form inform consent obtain subject 's legal guardian 15 . Females must lactate pregnant Screening Baseline ( document negative betahuman chorionic gonadotropin [ ß hCG ] test minimum sensitivity 25 IU/L equivalent unit ß hCG ) . A separate baseline assessment require negative screening pregnancy test obtain 72 hour first dose study drug 16 . All female consider childbearing potential unless postmenopausal ( amenorrheic least 12 consecutive month , appropriate age group without know suspected cause ) sterilize surgically ( i.e . bilateral tubal ligation , total hysterectomy bilateral oophorectomy , surgery least one month dose ) 17 . Willing able comply aspect protocol 1 . Presence Screening FVIII inhibitor ≥ 0.6 BU test Nijmegen modification Bethesda assay either central local laboratory 2 . History FVIII inhibitor ≥ 0.6 BU measure use Nijmegen modification Bethesda assay 3 . History FVIII inhibitor ≥ 1.0 BU subject test routinely use original Bethesda assay , history period low recovery response Factor VIII treatment 4 . Demonstrated inability respond conventional dos FVIII therapy 5 . History incremental recovery Factor VIII &lt; 1.35 % per IU/kg infuse 6 . Hematological disorder blood coagulation disease ( e.g. , idiopathic thrombocytopenic purpura , von Willebrand disease , etc . ) hemophilia A 7 . Laboratory clinical evidence portal vein hypertension include , ( limited , INR &gt; 1.4 , presence splenomegaly and/or spider angioma physical examination and/or history esophageal hemorrhage document esophageal varix 8 . Uncontrolled hypertension ( diastolic blood pressure &gt; 100 mm Hg ) 9 . Hemoglobin &lt; 10 g.dL 10 . HIV disease symptom regardless presence HIV antibodies 11 . Routine administration ( plan routine administration course study ) , immunosuppressive immunomodulating drug antiretroviral therapy ( e.g. , steroid , betainterferon ) 12 . Severe renal dysfunction ( creatinine &gt; 2x upper limit normal [ ULN ] , total bilirubin &gt; 2x ULN ) 13 . Liver disease ( alanine aminotransferase [ ALT ] , aspartate aminotransferase [ AST ] &gt; 3x ULN ) 14 . History diabetes metabolic disease 15 . History hypersensitivity serious adverse reaction recombinant plasmaderived FVIII concentrate 16 . History pretreatment prior administration FVIII product ( e.g. , antihistamine ) 17 . Regular use antifibrinolytics medication affect platelet function 18 . Hypersensitivity hamsteror mouse derive protein 19 . Blood transfusion within 30 day enrollment study 20 . Current participation another investigational drug device study , participate clinical study involve investigational drug device within 30 day enrollment study 21 . Unable unwilling cooperate study procedure</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>GreenGene™F , Previously Treated Patients</keyword>
</DOC>